A Study of Soticlestat in Adults and Children With Rare Epilepsies

NCT03635073 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

156

Enrollment

INDUSTRY

Sponsor class

Stopped Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-18-001 study is no longer necessary. Therefore, Takeda has made a decision to close this study

Conditions

Epilepsy
Dravet Syndrome (DS)
Lennox-Gastaut Syndrome (LGS)

Interventions

DRUG: Soticlestat

Sponsor

Takeda